In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 15 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Association of M235T polymorphism of angiotensinogen gene and lipid parameters in heart failure patients with type 2 diabetes mellitus.

Session Poster session 3

Speaker Olena Medentseva

Event : Heart Failure 2017

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Poster Session

Authors : OO Medentseva (Kharkiv,UA), MM Udovychenko (Kharkiv,UA), IS Rudyk (Kharkiv,UA)

OO Medentseva1 , MM Udovychenko1 , IS Rudyk1 , 1L.T.Malaya Institute of Therapy, Department of Clinical Pharmacology and Pharmagenetics of non-communicable diseases - Kharkiv - Ukraine ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 513

Background. Polymorphism of angiotensinogen (ATG) gene M235T could be associated with coronary artery disease (CAD). Dyslipidemia have been reported as one of the main pathophysiological mechanism contributing to CAD. It’s well known that arterial hypertension and CAD play an important role in unfavorable course of heart failure with preserved ejection fraction (HFpEF) development. On the other hand, the association of M235T polymorphism of ATG gene and lipid parameters in heart failure patients with type 2 diabetes mellitus (T2DM) is not well researched.

Purpose. To investigate the parameters of lipid metabolism in diabetic and non-diabetic subjects carrying different types of M235T polymorphism of ATG with HFpEF.

Methods. One hundred and thirty-three patients (58 males and 75 females; mean age 61,78±9,7 years) with HFpEF were examined. One hundred patients were carriers of 235T allele (MT + TT genotypes), 33 patients were homozygous carriers of 235M allele of M235T polymorphism of ATG. T2DM had 83 patients and 49 were non-diabetic patients. By using of polymerase chain reaction, different genotypes of M235T polymorphism of ATG were determined. The lipid metabolism parameters were performed by using kits of reagents "NUMAN" (Germany). Continuous variables as median (25th, 75th percentile) are expressed. Mann-Whitney U test was used for nonparametric comparisons. All statistical tests were 2-tailed and p<0,05 was considered statistically significant.

Results. In the group of T2DM subjects levels of serum total cholesterol ((6,00 (5,00 : 6,80) vs to 5,10 (4,30 : 5,90) mmol/l), very low-density lipoprotein-cholesterol ((0,92 (0,62 : 1,33) vs 0,69 (0,47 : 0,83) mmol/l) and triglycerides ((2,10 (1,50 : 2,95) vs 1,6 (1,15 : 1,85) mmol/l, respectively) were increased comparing with the group of non-diabetic patients, carrying the 235T allele of M235T polymorphism, (p<0,005). No significant differences in lipids parameters such as levels of serum total cholesterol ((5,85 (4,57 : 7,05) vs to 5,65 (4,7 : 6,77) mmol/l), very low-density lipoprotein-cholesterol ((0,88 (0,67 : 1,15) vs 0,85 (0,55 : 0,98) mmol/l) and triglycerides ((2,05 (1,80 : 2,57) vs 1,9 (1,22 : 2.20) mmol/l) were found in M235M carriers with T2DM and without it, respectively, (p > 0,05).

Conclusions: The most unfavorable lipid parameters profile had diabetic patients with HFpEF and MT + TT genotypes of M2335T polymorphism of ATG.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are